Evolving trends of antidiabetic agents stratified by age, kidney function and body mass index: Insights from a nationwide claims database
Authors' conclusion
In this large-scale analysis, SGLT2i use increased substantially across diverse individual traits, supporting their integration into diverse clinical contexts in real-world practice. Our findings may provide valuable insights into diabetes care in the forthcoming era of super-aged societies.
Study context
- Population
- Adults with T2D receiving at least one antidiabetic prescription, large-scale database, Japan, 2015–2024
- Outcome
- Annual prescription rates by antidiabetic drug class, overall and stratified by age, sex, HF status, eGFR, BMI, HbA1c and clinical setting
Methodological detailsnationwide claims database, 2015–2024
- Nationwide claims database
- 2015–2024
Main finding
As reported in the abstract
SGLT2i prescription rate · 2015 to 2024
SGLT2i prescriptions in 2015
4.1%
95% CI 4.0%–4.2%
SGLT2i prescriptions in 2024
38.9%
95% CI 38.7%–39.0%
Observational data: associations, not effects.
Further findings
SGLT2i prescription rate, aged ≥80 years · 2024
- Temporal increase in SGLT2i prescriptions, aged ≥80 years, in 2024
- 33.1% (95% CI, 32.8%-33.3%)
GLP-1 RA prescription rate · 2024
- GLP-1 RA prescriptions in 2024
- 8.0% (95% CI, 7.9%-8.1%)
- Upward trend among individuals aged <65 years and with obesity, especially after launch of oral semaglutide in 2021
Original publication
Evolving trends of antidiabetic agents stratified by age, kidney function and body mass index: Insights from a nationwide claims database. Diabetes Obes Metab. Published 2 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →